Proton Pump Inhibitors

@article{Richardson2012ProtonPI,
  title={Proton Pump Inhibitors},
  author={P Richardson and Christopher J. Hawkey and William A. Stack},
  journal={Drugs},
  year={2012},
  volume={56},
  pages={307-335}
}
Proton pump inhibitors (PPIs) are drugs which irreversibly inhibit proton pump (H+/K+ ATPase) function and are the most potent gastric acid-suppressing agents in clinical use. There is now a substantial body of evidence showing improved efficacy of PPIs over the histamine H2 receptor antagonists and other drugs in acid-related disorders.Omeprazole 20 mg/day, lansoprazole 30 mg/day, pantoprazole 40 mg/day or rabeprazole 20 mg/day for 2 to 4 weeks are more effective than standard doses of H2… Expand

Paper Mentions

Clinical Pharmacology of Proton Pump Inhibitors
TLDR
Data is discussed that may help clinicians choose between the available PPIs for specific clinical situations and indications, and chemical, pharmacodynamic and pharmacokinetic differences among these drugs that may make certain ones more, or less, suitable for treating different patient subgroups. Expand
A review of proton-pump inhibitors
TLDR
Proton-pump inhibitors have superseded the use of histamine-2-receptor antagonists in patients with moderate to severe gastric acid-related diseases, as well as for the prophylaxis of upper gastrointestinal injury, for example, with nonsteroidal anti-inflammatory drugs. Expand
Chapter 4 – Omeprazole
Publisher Summary Omeprazole is a proton pump inhibitor that inhibits secretion of gastric acid by irreversibly blocking the enzyme system of hydrogen/potassium adenosine triphosphatase, the “protonExpand
Current Pharmacological Management of Gastroesophageal Reflux Disease
TLDR
The current and developing therapeutic agents for GERD treatment are summarized and development of novel therapeutic agents has focused on the underlying mechanisms of GERD, such as transient lower esophageal sphincter relaxation, motility disorder, mucosal protection, and esophileal hypersensitivity. Expand
Pantoprazole Decreases Cell Viability and Function of Human Osteoclasts In Vitro
TLDR
The bone degrading and resorptive function of osteoclasts is inhibited by the administration of proton pump inhibitors, and PPI-related fractures through “basic multicellular unit” dysfunction are unlikely. Expand
Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case–control study
TLDR
PPI/H2RA use, in a UK population, was not associated with pancreatic cancer risk and no consistent patterns of association were seen when cumulative exposure to these drugs was examined separately or together. Expand
In search of the grail: A race for acid suppression
TLDR
The present review is focused on the mechanisms of action, pharmacokinetic properties, and technological advances for increasing the pharmacologic performance of a proton pump inhibitor. Expand
An assessment of human gastric fluid composition as a function of PPI usage
TLDR
Assessment of bacterial concentrations by flow cytometry revealed that PPIs did not cause a profound increase in microbial load in the gastric fluid, further delineate the profound effects that PPI usage has on the physiology of the stomach. Expand
Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data.
TLDR
The results clearly indicate that in contrast to PPIs, which seem to affect itraconazole bioavailability mainly via intragastric pH changes, coadministered Coca-Cola is likely to alter a range of gastrointestinal parameters relevant to in vivo dissolution rather than solely affecting the intragASTric pH. Expand
Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?
  • M. Lettino
  • Medicine
  • European journal of internal medicine
  • 2010
TLDR
Important questions concerning a true interference between the two classes of drugs still remain unanswered and need to be addressed by adequately powered studies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 297 REFERENCES
Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
TLDR
Omeprazole plus amoxicillin appears to be better tolerated than triple therapy and represents a first-line treatment alternative in patients with H. pylori-associated peptic ulcer disease. Expand
Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients.
TLDR
Pantoprazole provides fast healing of acute duodenal ulcer as well as rapid improvement of ulcer symptoms in patients with peptic ulcer disease. Expand
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
TLDR
Lansoprazole was superior to ranitidine in symptom relief and healing of gastro-oesophageal reflux disease and tended to relieve symptoms more rapidly than omeprazole, although initial healing was similar. Expand
Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
TLDR
Omeprazole was significantly better than continued H2 receptor antagonist treatment for the short term management of refractory peptic ulcer as judged by healing rate and pain relief, and it was safe. Expand
The chemotherapeutic effects of H+/K+ inhibitors on Helicobacter pylori infection.
  • R. Logan
  • Medicine
  • Pharmacology & therapeutics
  • 1996
TLDR
Dual therapy (omeprazole with either amoxycillin or clarithromycin) is a more logical and highly effective alternative to standard triple therapy, with fewer side effects and better patient compliance, however, H. pylori eradication regimens based on a PPI and two antimicrobials will be the first-line treatment for H.pylori gastritis and peptic ulcer in the future. Expand
Profound Gastric Acid Inhibition: Advantages and Potential Hazards
TLDR
The first H+-K+ ATPase antagonist omeprazole is the most potent gastric acid-reducing agent currently known and achieves faster healing and symptom relief of duodenal ulcer than H2 receptor blockers. Expand
Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.
TLDR
From results, it is expected that rabeprazole inhibited H. pylori urease activity by forming disulfide bonds between it and the active site of the enzyme. Expand
A trial of lansoprazole in refractory gastric ulcer.
TLDR
Lansoprazole 30 or 60 mg/day appear equally effective in healing refractory gastric ulcers, while maintenance therapy of 30 mg/ day effectively prevented an ulcer relapse. Expand
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
TLDR
Treatment with high-dose famotidine significantly reduces the cumulative incidence of both gastric and duodenal ulcers in patients with arthritis receiving long-term NSAID therapy. Expand
Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
TLDR
The PPI strategy appears cost effective relative to the standard-dose H2RA strategy in the following situations: when patients are significantly bothered by esophagitis and in institutional settings where the difference in drug costs between PPIs and H2RAs is small. Expand
...
1
2
3
4
5
...